De Novo Drug Design
Fragment Growing & Linking 
Deep Learning Generation 
IP-First Design De novo design generates novel molecular structures with desired properties from scratch—complementing screening by inventing chemical matter that does not yet exist in any library.
Why De Novo Drug Design Is the Critical Bridge Between Empty Pocket and Novel Lead?
Virtual screening finds what is already in the catalog. De novo design invents what is not. For seed-stage biotechs facing patent thickets or scaffold fatigue, this means accessing intellectual property space beyond existing chemical collections. For pharma teams targeting novel binding sites, it means generating custom ligands that fit the pocket geometry precisely—rather than forcing a known scaffold into an unfamiliar cavity.
What Sets the Platform Apart
Structure-Based Fragment Assembly
Fragments docked into the binding site are grown or linked in situ to build novel ligands atom-by-atom or fragment-by-fragment.
Ligand-Based SAR-Driven Design
3D-QSAR and SAR data guide the construction of bioisosteric replacements and scaffold hops without target structure.
Deep Learning Generation
Transformer and reinforcement learning models generate SMILES strings optimized for potency, selectivity, and ADMET Prediction & Modeling in a single design cycle.
The De Novo Drug Design Suite
Structure-Based De Novo Design (SBDND)
Fragment Growing and Linking in the Binding Pocket
- Fragment Growing — A seed fragment is docked into the binding site and extended by adding favorable functional groups, atoms, or rings to optimize interactions with surrounding residues.
- Fragment Linking — Multiple small fragments docked at distinct subsites are connected by linkers to form a single complex molecule that bridges the pocket.
- Site Point Connection — Unique site locations within the binding pocket are identified for precise fragment placement before growth or linkage.
- Ideal For — Well-characterized binding sites with known hot spots; Lead Optimization follow-up; escaping patent-protected cores.
For virtual biotechs with a crystal structure but no viable hits from screening, SBDND constructs ligands directly inside the pocket. For pharma teams, fragment linking enables rational design of bitopic or bifunctional ligands that engage multiple subsites simultaneously.
Ligand-Based De Novo Design (LBDND)
SAR-Guided Scaffold Construction
- Bioisosteric Replacement — Functional groups with similar physicochemical properties are swapped to maintain activity while altering patentability or metabolic stability.
- Scaffold Reconstruction — Active fragments are reassembled into novel cores using 3D-QSAR constraints and shape matching.
- Random and Directed Connection — Fragments are connected via random sampling or evolutionary algorithms guided by fitness scoring.
- Ideal For — Targets without crystal structures; series rescue; Scaffold Hopping Analysis campaigns.
When the receptor structure is unavailable, LBDND leverages existing SAR knowledge to construct new ligands. Ligand-Based Pharmacophore Generation defines the essential feature set, and 3D-QSAR guides the assembly of novel scaffolds that preserve the binding signature.
AI-Driven Generative Design
Deep Learning for Novel Molecular Invention
- Transformer-Based SMILES Generation — Autoregressive language models generate valid molecular structures token-by-token, conditioned on target-specific scoring functions.
- Reinforcement Learning Optimization — Generated molecules are iteratively refined via reward functions balancing potency, selectivity, and synthetic accessibility.
- Multi-Objective Optimization — Simultaneous optimization of binding affinity, ADMET Prediction & Modeling, and novelty scores.
- Ideal For — Ultra-large chemical space exploration; patent-free lead generation; De Novo Drug Design campaigns requiring rapid iteration.
Generative AI transcends fragment libraries. For biotechs seeking first-in-class leads, deep learning models invent scaffolds that human medicinal chemists might never conceive—then optimize them for developability before synthesis.
Platform Instrumentation
| Software / System | Core Capability |
|---|---|
| REINVENT 4 | Industrial-grade transformer-based generative platform with reinforcement learning for multi-objective molecular optimization and scaffold decoration. |
| Schrödinger Glide + Prime | Fragment docking, growing, and linking with OPLS4 force field; induced-fit refinement. |
| MOE / ICM-Pro | Fragment-based design, bioisosteric replacement, and 3D-QSAR-guided scaffold reconstruction. |
| AutoDock Vina 1.2.0 | Fragment pose prediction and seed docking for structure-based growing protocols. |
| RDKit + scikit-learn | Molecular descriptor calculation, fragment fingerprint matching, and custom QSAR model development. |
| PyTorch / TensorFlow | Transformer and GNN training for generative molecular design and reinforcement learning loops. |
| NVIDIA A100 GPU Cluster | Parallelized generative model sampling and billion-fragment virtual screening. |
| PyMOL + Maestro | Fragment visualization, growing trajectory inspection, and interaction analysis. |
Standardized Workflow
Project Workflow
A standardized, milestone-driven execution system. From target or active data to novel designed candidates—managed by a single computational project team, tracked in real time.
01 Target / Active Data Review
- Target structure review: PDB, AlphaFold, or Homology Modeling & Threading.
- Known active compound collection for LBDND or AI training.
- Binding site mapping and hot spot identification.
Deliverable: Target profile + binding site map.
02 Design Strategy Selection
- Strategy selection: SBDND fragment growing/linking, LBDND SAR-driven, or AI generative.
- Fragment library selection or generative model configuration.
- Scoring function definition: docking score, QSAR, or multi-objective reward.
Deliverable: Design strategy with scoring parameters.
03 De Novo Generation Execution
- Fragment docking and growing, or SMILES generation via transformer models.
- Linker design and connection optimization.
- Diversity filter enforcement to ensure structural novelty.
Deliverable: Generated candidate set with novelty metrics.
04 Candidate Evaluation & Ranking
- Docking rescoring and Binding Free Energy Calculation (FEP/TI, MM/PBSA) for top candidates.
- ADMET Prediction & Modeling filtering and synthetic accessibility scoring.
- Molecular Dynamics (MD) Simulations for pose stability (if contracted).
Deliverable: Evaluated subset with stability and developability metrics.
05 Report & Handoff
- Final ranked candidate list with IP novelty assessment.
- Structural rationale and proposed synthesis route.
- Direct handoff to Hit Biophysical Characterization or synthesis team.
Deliverable: Final report + data package + transition plan to Hit to Lead or Lead Optimization.
Sample Requirements
| Requirement | Details |
|---|---|
| Target structure | PDB ID, AlphaFold model, or Homology Modeling & Threading for SBDND; not required for LBDND |
| Known actives | 3–10+ confirmed actives with SAR data for LBDND; optional for AI generative model training |
| Project scope | Novel lead generation, scaffold replacement, or series expansion |
| Prior data | Existing docking, QSAR, or ADMET flags to guide design constraints |
| IP constraints | Known patent claims or scaffold classes to avoid |
Standard Deliverables
- Target binding site map with hot spot and fragment position annotations
- Generated candidate set (100–500) with structural novelty and synthetic accessibility metrics
- 3D poses and interaction fingerprints for structure-based designs
- Predicted activity scores and ADMET profiles for AI-generated candidates
- Electronic data package formatted for synthesis or Structure-Based Virtual Screening (SBVS) validation
Frequently Asked Questions
Case Study
Case Study: REINVENT 4 — Industrial-Grade Generative Molecule Design
Published Evidence:
Loeffler HH, et al. REINVENT 4: Modern AI–driven generative molecule design. J Cheminform. 2024;16:20.
Key Findings:
- Transformer Architecture: REINVENT 4 employs a transformer-based generative model with reinforcement learning for multi-objective molecular optimization, supporting scaffold decoration, fragment linking, and curriculum learning.
- Transfer Learning: A pre-trained general prior is focused via transfer learning on project-specific compound sets, accelerating convergence toward relevant chemical subspaces.
- Scoring Flexibility: Composite scoring functions integrate docking scores, predictive QSAR models, and custom ADMET filters within a unified reward framework.
From Algorithm to Novel Chemistry:
For seed-stage biotechs, REINVENT 4 demonstrates that transformer-based generation with reinforcement learning can replace manual scaffold exploration—delivering patent-clear candidates with optimized developability profiles in days rather than months. For pharma teams, the modular scoring architecture enables seamless integration of proprietary docking and ADMET models, ensuring generated compounds align with internal developability criteria. Our platform operationalizes this peer-reviewed framework within an audit-ready workflow, pairing REINVENT 4 with Protein-Ligand Docking (Rigid / Flexible / Induced Fit Docking) validation and Binding Free Energy Calculation (FEP/TI, MM/PBSA) to confirm that AI-invented molecules withstand experimental scrutiny.
Figure 1. REINVENT 4 generative modes: de novo generation (Reinvent), scaffold decoration (Libinvent), fragment linking (Linkinvent), and similarity-bounded optimization (Mol2Mol). (Loeffler HH, et al. 2024)
Reference
- Loeffler HH, et al. REINVENT 4: Modern AI–driven generative molecule design. J Cheminform. 2024;16:20.
Need to invent novel chemical matter for your target? Our team can design a de novo campaign tailored to your pocket geometry, SAR data, and IP requirements. Contact our scientific team today to start your project.
